Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. reports developments for a life sciences tools company whose primary business is conducted through Enzo Life Sciences. The business focuses on labeling and detection technologies from DNA to whole cell analysis, with products that include antibodies, genomic probes, assays, biochemicals, and proteins, and it monetizes its technology through product sales, global distribution, and licensing.
Company news commonly covers fiscal results, operating cash flow, EBITDA and Adjusted EBITDA measures, product and market-demand updates, cash dividends, debt repayment, governance changes, and the completed transfer of common stock trading from the NYSE to OTCQX under the symbol ENZB.
Enzo Biochem, Inc. (NYSE:ENZ) has partnered with CPESN NY to provide COVID-19 testing at 52 independent pharmacies across New York. This initiative aims to enhance community access to testing, essential during the pandemic. The program leverages Enzo's AMPIPROBE® SARS-CoV-2 swab molecular test, known for its rapid results within two to three days. Enzo's extensive experience in diagnostics and support services bolsters this effort, offering reliable testing solutions to communities in need.
Enzo Biochem, Inc. (NYSE: ENZ) has received Emergency Use Authorization (EUA) from the FDA for its AMPIPROBE® SARS-CoV-2 Test System, allowing use on three platforms: its own GENFLEX™ platform, Qiagen’s QIAsymphony® SP, and a manual workflow. This authorization enables laboratories to utilize the test without additional validation. The AMPIPROBE® system includes components for sample collection, processing, and detection, aimed at addressing COVID-19 testing needs amidst supply limitations.
Enzo Biochem partners with Farmingdale State College to provide molecular and antibody testing for COVID-19 as the college reopens. This collaboration falls under Enzo's School and Institution Testing (SIT) Program, aiming to ensure safety and compliance for students and staff. Testing will be available to all campus members at no financial cost, leveraging Enzo's Long Island-based resources. The initiative includes onsite testing clinics and prioritizes immediate testing needs. Enzo aims to support educational institutions nationwide with similar COVID-19 testing solutions.
Enzo Biochem reported third quarter revenues of $16.9 million, a 14% decline from last year, primarily due to COVID-19 impacts. The company faced a net loss of ($9.9) million or ($0.21 per share). Clinical Services revenue decreased to $10.5 million, driven by a 28% reduction in accession volume. Despite challenges, Enzo launched an extensive COVID-19 program and saw improvements in clinical services gross margins, now at 12.9%. Cash and equivalents reached $55 million, indicating proactive financial management amid ongoing challenges.
Enzo Biochem, Inc. (NYSE: ENZ) will announce its third quarter 2020 financial results on June 8, 2020, after market close. Following the release, President Barry Weiner and CFO David Bench will host a conference call at 5:00 PM ET to discuss the financial results and address investor questions. The call will be accessible via an audio webcast.